effects of Progesterone by vaginal suppository to reduce preterm birth in women at risk

Comparison effects of Progesterone by vaginal suppository and betamimetics to reduce preterm birth in women at risk

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108286808N2

Enrollment

Registered

2012-02-04

Start date

2008-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm delivery. Pregnancy, childbirth and the puerperium

Interventions

Intervention 1: In the case group Progesterone supp was administrated every 2days until the end of 34 week of pregnancy. Intervention 2: In the control group betamimetics (syrp. Or tab salbutamol or t

Treatment - Drugs

In the case group Progesterone supp was administrated every 2days until the end of 34 week of pregnancy.

In the control group betamimetics (syrp. Or tab salbutamol or tab isoxoprin) until the end of 34 week of pregnancy.

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: cervical insufficiency, history of premature labor and uterine abnormalities. Exclusion criteria : fetal abnormalities, preeclampsia, and sensitivity to progesterone

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of days delay in delivery of prescribed suppositories. Timepoint: during labor. Method of measurement: Counting the days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hasan Namaaie

Birjand University of Medical Science

mhnamaei@hotmail.com+98 56 1444 3041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026